miR-511-3p protects against cockroach allergen–induced lung inflammation by antagonizing CCL2

Danh, C.; Mu, Jie; Xia, Ke; Sachdeva, Karan; Qin, Zili; Wan, Mei; Ishmael, Faoud T.; Gao, Peisong

doi:10.1172/jci.insight.126832

Cited by 30 publications

(26 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, the activation of RhoA signalling has been previously associated with macrophage polarisation 86,87 . Our study provided further evidence that CCL2 can activate RhoA signalling that plays a key role in mediating CCL2‐driven macrophage M1 polarisation 46 . In addition to its role in macrophage polarisation, McPhillips et al 88 report that RhoA signalling also plays a significant role in the uptake of apoptotic cells by alveolar macrophages.…”

Section: Rhoa/rho‐kinase and Airway Inflammationsupporting

confidence: 71%

“…Thus, molecules regulating macrophage polarisation and function are valuable for the treatment of allergic asthma. We have shown that RhoA signalling is critical in controlling macrophage polarisation through the CCL2/CCR2 axis 46 . In fact, the activation of RhoA signalling has been previously associated with macrophage polarisation 86,87 .…”

Section: Rhoa/rho‐kinase and Airway Inflammationmentioning

confidence: 75%

“…IL‐17A can also augment contraction of the airway smooth muscle through activating NF‐κβ‐RhoA‐ROCK2 signalling cascade 45 . In addition, our recent studies suggest that CCL2 can activate RhoA signalling that contributes to macrophage polarisation and subsequently the development of allergic airway inflammation 46 …”

Section: Cytokine Regulation Of Rhoa/rho‐kinase Activationmentioning

confidence: 99%

“…MicroRNAs (miRNAs), specifically miR‐133a, have been recently reported to regulate RhoA protein expression (Figure 3). 47 miRNAs are small, non‐coding sequences of single‐stranded RNAs that negatively modulate the expression of various genes 24,46 . They bind to the 3′‐untranslated region (UTR) of the target mRNAs resulting in cleavage of mRNA and repression of translation 24 .…”

Section: Epigenetic Regulation Of Rhoa/rho‐kinase Activationmentioning

confidence: 99%

See 3 more Smart Citations

RhoA/Rho‐kinases in asthma: from pathogenesis to therapeutic targets

et al. 2020

Self Cite

View full text Add to dashboard Cite

Asthma is a chronic and heterogeneous disease characterised by airway inflammation and intermittent airway narrowing. The key obstacle in the prevention and treatment of asthma has been our incomplete understanding of its aetiology and biological mechanisms. The ras homolog family member A (RhoA) of the Rho family GTPases has been considered to be one of the most promising and novel therapeutic targets for asthma. It is well known that RhoA/Rho-kinases play an important role in the pathophysiology of asthma, including airway smooth muscle contraction, airway hyper-responsiveness, b-adrenergic desensitisation and airway remodelling. However, recent advances have suggested novel roles for RhoA in regulating allergic airway inflammation. Specifically, RhoA has been shown to regulate allergic airway inflammation through controlling Th2 or Th17 cell differentiation and to regulate airway remodelling through regulating mesenchymal stem cell (MSC) differentiation. In this review, we evaluate the literature regarding the recent advances in the activation of RhoA/Rho-kinase, cytokine and epigenetic regulation of RhoA/Rho-kinase, and the role of RhoA/Rho-kinase in regulating major features of asthma, such as airway hyperresponsiveness, remodelling and inflammation. We also discuss the importance of the newly identified role of RhoA/Rho-kinase signalling in MSC differentiation and bronchial epithelial barrier dysfunction. These findings indicate the functional significance of the RhoA/Rho-kinase pathway in the pathophysiology of asthma and suggest that RhoA/Rho-kinase signalling may be a promising therapeutic target for the treatment of asthma.

show abstract

Section: Rhoa/rho‐kinase and Airway Inflammationsupporting

confidence: 71%

Section: Rhoa/rho‐kinase and Airway Inflammationmentioning

confidence: 75%

Section: Cytokine Regulation Of Rhoa/rho‐kinase Activationmentioning

confidence: 99%

Section: Epigenetic Regulation Of Rhoa/rho‐kinase Activationmentioning

confidence: 99%

See 2 more Smart Citations

RhoA/Rho‐kinases in asthma: from pathogenesis to therapeutic targets

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…CCL2 secreted from cancerassociated mesothelial cells promotes peritoneal metastasis of ovarian cancer cells through the P38-MAPK pathway [23]. CCL2 is highly expressed in M2 macrophages but antagonized by miR-511-3p, and miR-511-3p regulates allergic inflammation and macrophage polarization by targeting CCL2 and its downstream Ccr2/RhoA axis [24]. However, the role of these genes in LUAD development has not been reported.…”

Section: Discussionmentioning

confidence: 99%

Establishment and Evaluation of a 6-Gene Survival Risk Assessment Model Related to Lung Adenocarcinoma Microenvironment

Wang

Zhu

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

Objective. A survival risk assessment model associated with a lung adenocarcinoma (LUAD) microenvironment was established and evaluated to identify effective independent prognostic factors for LUAD. Methods. The public data were downloaded from the TCGA database, and ESTIMATE prediction software was used to score immune cells and stromal cells for tumor purity prediction. The samples were divided into the high-score group and the low-score group by the median value of the immune score (or stromal score). The Wilcoxon test was used for differential analysis. GO and KEGG enrichment analysis of differentially expressed genes (DEGs) was performed using “clusterProfiler” of R package. Meanwhile, univariate and multivariate regression analysis was performed on DEGs to construct a multivariate Cox risk regression model with variable gene expression levels as independent prognostic factors affecting a tumor microenvironment (TME) and tumor immunity. Results. This study found that LUAD patients with high immune cell (stromal cell) infiltration had better prognosis and were in earlier staging. Functional enrichment analysis revealed that most DEGs were related to the proliferation and activation of immune cells or stromal cells. A survival prediction model composed of 6 TME-related genes (CLEC17A, TAGAP, ABCC8, BCAN, FLT3, and CCR2) was established, and finally, the 6 feature genes closely related to the prognosis of LUAD were proved. The AUC value of the ROC curve in this model was 0.7, indicating that the model was reliable. Conclusion. Six genes related to the LUAD microenvironment have a predictive prognostic value in LUAD.

show abstract

Targeting tumor‐associated macrophages: A potential treatment for solid tumors

Chen

Jin

Song

et al. 2020

Journal Cellular Physiology

View full text Add to dashboard Cite

Tumor‐associated macrophages (TAMs) in solid tumors exert protumor activities by releasing cytokines or growth factors into the tumor microenvironment. Increasing studies have also shown that TAMs play a key role in tumor progression, such as tumor angiogenesis, immunosuppression, cell proliferation, migration, invasion, and metastasis. A large body of evidence shows that the abundance of TAMs in solid tumors is correlated with poor disease prognosis and resistance to therapies. Therefore, targeting TAMs in solid tumors is considered to be a promising immunotherapeutic strategy. At present, the therapeutic strategies of targeting macrophages mainly include limiting monocyte recruitment, depletion strategies, promoting macrophage phagocytic activity, and induction of macrophage reprogramming. Additionally, targeting TAMs in combination with conventional therapies has been demonstrated to be a promising therapeutic strategy in solid tumors. In the present review, we summarized various TAMs‐targeting therapeutic strategies for treating solid tumors. This review also discusses the challenges for targeting TAMs as tumor treatments, the obstacles in clinical trials, and the perspective for the future development of TAMs‐targeting therapies for various cancers.

show abstract

miR-511-3p protects against cockroach allergen–induced lung inflammation by antagonizing CCL2

Cited by 30 publications

References 68 publications

RhoA/Rho‐kinases in asthma: from pathogenesis to therapeutic targets

RhoA/Rho‐kinases in asthma: from pathogenesis to therapeutic targets

Establishment and Evaluation of a 6-Gene Survival Risk Assessment Model Related to Lung Adenocarcinoma Microenvironment

Targeting tumor‐associated macrophages: A potential treatment for solid tumors

Contact Info

Product

Resources

About